Acute myeloid leukemia in the older adults

[1]  A. Hagemeijer,et al.  Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  S. Yamasaki,et al.  Impact of age on outcomes of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in elderly patients with acute myeloid leukemia , 2016, American journal of hematology.

[3]  G. Garcia-Manero,et al.  Final Results from a Phase 2 Study of Pracinostat in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) , 2015 .

[4]  L. Pleyer,et al.  Azacitidine in Older Patients with Acute Myeloid Leukemia (AML). Results from the Expanded International E-Alma Series (E-ALMA+) According to the MRC Risk Index Score , 2015 .

[5]  F. Ravandi,et al.  SGN-CD33A Plus Hypomethylating Agents: A Novel, Well-Tolerated Regimen with High Remission Rate in Frontline Unfit AML , 2015 .

[6]  H. Einsele,et al.  Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. , 2015, The Lancet. Oncology.

[7]  M. Bottai,et al.  The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma – a Swedish population-based study , 2015, BMC Cancer.

[8]  C. Thom.  Preliminary data on ASP2215: tolerability and efficacy in acute myeloid leukemia patients. , 2015, Future oncology.

[9]  R. Greil,et al.  International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. , 2015, Blood.

[10]  D. Blaise,et al.  Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the EBMT , 2015, Haematologica.

[11]  P. Vyas,et al.  An immunophenotypic pre‐treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+ CD38low blasts , 2015, British journal of haematology.

[12]  E. Stein.  IDH2 inhibition in AML: Finally progress? , 2015, Best practice & research. Clinical haematology.

[13]  M. Wetzler,et al.  Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia , 2015, American journal of hematology.

[14]  J. Lipton,et al.  Modified EBMT Pretransplant Risk Score Can Identify Favorable-risk Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for AML, Not Identified by the HCT-CI Score. , 2015, Clinical lymphoma, myeloma & leukemia.

[15]  F. Lo‐Coco,et al.  Minimal residual disease negativity in elderly patients with acute myeloid leukemia may indicate different postremission strategies than in younger patients , 2015, Annals of Hematology.

[16]  W. Wood,et al.  Use of ED and hospital services for patients with acute leukemia after induction therapy: one year follow-up. , 2015, Leukemia research.

[17]  M. Konopleva,et al.  Phase I/II trial of the combination of midostaurin (PKC412) and 5‐azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome , 2015, American journal of hematology.

[18]  C. Reyes,et al.  Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States , 2015, Annals of Hematology.

[19]  L. Möllgård,et al.  Characterization and prognostic features of secondary acute myeloid leukemia in a population‐based setting: A report from the Swedish Acute Leukemia Registry , 2015, American journal of hematology.

[20]  L. Pleyer,et al.  Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction. , 2015, Leukemia research.

[21]  R. Hills,et al.  A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia , 2015, Leukemia.

[22]  E. Estey,et al.  Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in older adults. , 2014, Hematology. American Society of Hematology. Education Program.

[23]  H. Klepin.  Geriatric perspective: how to assess fitness for chemotherapy in acute myeloid leukemia. , 2014, Hematology. American Society of Hematology. Education Program.

[24]  D. Neuberg,et al.  De novo acute myeloid leukemia with 20–29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study , 2014, American journal of hematology.

[25]  E. Estey,et al.  Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Tooze,et al.  The prognostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML). , 2014, Leukemia research.

[27]  K. Döhner,et al.  Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. , 2014, Blood.

[28]  R. Larson,et al.  Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients , 2014, Haematologica.

[29]  R. Stauder,et al.  The relevance of a geriatric assessment for elderly patients with a haematological malignancy--a systematic review. , 2014, Leukemia research.

[30]  R. Hills,et al.  The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial , 2014, Leukemia.

[31]  B. V. van Munster,et al.  The effect of a geriatric evaluation on treatment decisions for older cancer patients – a systematic review , 2014, Acta oncologica.

[32]  R. Stauder,et al.  The G8 screening tool detects relevant geriatric impairments and predicts survival in elderly patients with a haematological malignancy , 2014, Annals of Hematology.

[33]  H. Kantarjian,et al.  Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  H. Klepin.  Predicting treatment outcomes in older patients with acute myelogenous leukemia. , 2013, Clinical advances in hematology & oncology : H&O.

[35]  R. Hills,et al.  Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. , 2013, Blood.

[36]  H. Kantarjian,et al.  Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low‐dose cytosine arabinoside in elderly patients with acute myeloid leukemia , 2013, Cancer.

[37]  A. Almeida,et al.  Efficacy and tolerability of 5-day azacytidine dose-intensified regimen in higher-risk MDS , 2013, Annals of Hematology.

[38]  M. Lübbert,et al.  Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome , 2013, Haematologica.

[39]  M. Minden,et al.  Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  N. Socci,et al.  Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. , 2012, The New England journal of medicine.

[41]  B. Quesnel,et al.  Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias , 2011, Leukemia.

[42]  S. Studenski,et al.  Gait speed and survival in older adults. , 2011, JAMA.

[43]  W. Hiddemann,et al.  Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes , 2010, The Lancet.

[44]  H. Kantarjian,et al.  Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. , 2010, Blood.

[45]  J. Williamson,et al.  Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. , 2010, Blood.

[46]  G. Ehninger,et al.  A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. , 2010, Blood.

[47]  H. Dombret,et al.  Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  K. Metzeler,et al.  Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  Lucy Skrabanek,et al.  MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. , 2009, Blood.

[50]  M. Minden,et al.  Outcomes and quality of care in acute myeloid leukemia over 40 years , 2009, Cancer.

[51]  Keith Wheatley,et al.  Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials , 2009, British journal of haematology.

[52]  H. Dombret,et al.  Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia , 2008, Haematologica.

[53]  W. Jędrzejczak,et al.  A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. , 2007, Blood.

[54]  B. Esterni,et al.  Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia , 2007, Cancer.

[55]  R. Hills,et al.  A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment , 2007, Cancer.

[56]  H. Kantarjian,et al.  The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. , 2007, British journal of haematology.

[57]  Susan O'Brien,et al.  Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome: , 2006, Cancer.

[58]  M. Sorror,et al.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. , 2005, Blood.

[59]  C. Earle,et al.  The outcomes and costs of acute myeloid leukemia among the elderly. , 2002, Archives of internal medicine.

[60]  P. Shekelle,et al.  The Vulnerable Elders Survey: A Tool for Identifying Vulnerable Older People in the Community , 2001, Journal of the American Geriatrics Society.

[61]  D. Grimwade,et al.  The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. , 2001, Blood.

[62]  M. Slovak,et al.  Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. , 1997, Blood.

[63]  R B Wallace,et al.  Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. , 1995, The New England journal of medicine.

[64]  L. Ferrucci,et al.  A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. , 1994, Journal of gerontology.

[65]  H. Tilly,et al.  Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  B. Löwenberg,et al.  On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  H. Chui,et al.  The Modified Mini-Mental State (3MS) examination. , 1987, The Journal of clinical psychiatry.

[68]  E. Pfeiffer.  A Short Portable Mental Status Questionnaire for the Assessment of Organic Brain Deficit in Elderly Patients † , 1975, Journal of the American Geriatrics Society.

[69]  E. Wattel,et al.  Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes. , 2014, Leukemia research.

[70]  R. Arceci.  Age-Related Prognostic Impact of Different Types of DNMT3A Mutations in Adults With Primary Cytogenetically Normal Acute Myeloid Leukemia , 2012 .

[71]  R. Arceci.  Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia , 2012 .

[72]  D. Brizel,et al.  National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .

[73]  Ack,et al.  LOWER-EXTREMITY FUNCTION IN PERSONS OVER THE AGE OF 70 YEARS AS A PREDICTOR OF SUBSEQUENT DISABILITY , 2001 .

[74]  M. Slovak,et al.  Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. , 1997, Blood.